Skip to main content
Publications
Rivero-Ferrer E , Olesen M, Plana E , Aguado J , Saigi-Morgui N , Rubino A, Daoud SZ, Lei A, Perez-Gutthann S , Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C . Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany . Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2
Winfree KB, Ainsworth C, Njue A , Molife C, Lyall M, Jen M-H, Bittoni M, Heyes A , Carbone DP. Defining aggressive disease in patients with advanced NSCLC receiving second-line treatment: a systematic review . Poster presented at the IASLC 19th World Conference on Lung Cancer; September 26, 2018. Toronto, Canada. [abstract] J Thorac Oncol. 2018 Oct; 13(10 (Suppl)):5908. doi: 10.1016/j.jtho.2018.08.1671
Samelson EJ, Miller PD, Christiansen C, Daizedeh NS, Grazette L, Anthony MS , Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk . J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043